←Back to Expert Scholars
Translational Medicine / 转化医学Checkpoint Combinations, Novel Immunotherapy
Adi Diab
MD
🏢MD Anderson Cancer Center🌐USA
Associate Professor of Melanoma Medical Oncology
45
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Adi Diab is a melanoma medical oncologist at MD Anderson who has led trials of novel IL-2 agonists including bempegaldesleukin and their combinations with checkpoint blockade. He conducts early-phase studies of emerging immunotherapy agents. His work explores combinatorial strategies to expand immunotherapy response.
Share:
🧪Research Fields 研究领域
IL-2 agonists
bempegaldesleukin
checkpoint combinations
melanoma immunotherapy
novel cytokines
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Adi Diab 的研究动态
Follow Adi Diab's research updates
留下邮箱，当我们发布与 Adi Diab（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment